FSA Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

FSA Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$2.81K	Hold	5	–	–	﹤0.01%	474
2025 Q2	$2.63K	Hold	5	–	–	﹤0.01%	446
2025 Q1	$3.17K	Hold	5	–	–	﹤0.01%	403
2024 Q4	$3.56K	Sell	5 -20	-80%	-$16.8K	﹤0.01%	422
2024 Q3	$26.3K	Buy	+25	New	+$27.8K	0.01%	211
2024 Q1	$4.81K	Hold	5	–	–	﹤0.01%	454
2023 Q4	$4K	Buy	+5	New	+$4.12K	﹤0.01%	469

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FSA Wealth Management's REGN Position: Q3 2025 in Review

FSA Wealth Management held its Regeneron Pharmaceuticals (REGN) position steady in Q3 2025 at 5 shares worth $2.81K. The position accounts for ﹤0.01% of the portfolio, ranked #474.

FSA Wealth Management first reported a position in REGN in Q4 2023 and has held it in 7 quarters since. The position peaked at $26.3K in Q3 2024. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

FSA Wealth Management held 5 shares of Regeneron Pharmaceuticals worth $2.81K as of Q3 2025.
FSA Wealth Management left its Regeneron Pharmaceuticals share count unchanged in Q3 2025.
Regeneron Pharmaceuticals made up ﹤0.01% of FSA Wealth Management's portfolio in Q3 2025, its #474 holding.
FSA Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 7 quarters since.
FSA Wealth Management's Regeneron Pharmaceuticals position peaked at $26.3K in Q3 2024.
1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on FSA Wealth Management's 13F filing for Q3 2025, filed 17 Nov 2025.